Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
Open Access
- 30 September 2007
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 43 (14), 2124-2133
- https://doi.org/10.1016/j.ejca.2007.07.010
Abstract
No abstract availableFunding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca
This publication has 28 references indexed in Scilit:
- Inhibition of poly(ADP-ribose) polymerase in cancerCurrent Opinion in Pharmacology, 2006
- Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinomaThe FASEB Journal, 2006
- Clinical perspectives of PARP inhibitorsPharmacological Research, 2005
- Chemopotentiation by PARP inhibitors in cancer therapyPharmacological Research, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repairOncogene, 2004
- Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break ResealingOnline Journal of Public Health Informatics, 2004
- The Therapeutic Potential of Poly(ADP-Ribose) Polymerase InhibitorsPharmacological Reviews, 2002
- Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system siteBlood, 2002
- Physiology and pathophysiology of poly(ADP‐ribosyl)ation *BioEssays, 2001